Overview
Robert Marsh is a Hematologist Oncology specialist and a Hematologist in Woodbridge, Virginia. Dr. Marsh is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Marsh is currently accepting new patients.
His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- POS
- PPO
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER MEDICARE
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- PPO
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE MAPD
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2280 Opitz Blvd, Suite 130, Woodbridge, VA 22191
210 W Shirley Ave, Warrenton, VA 20186
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
3 Clinical Trials
Lee Helman is an Oncologist in Bethesda, Maryland. Dr. Helman is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, and Adult Soft Tissue Sarcoma.
Skip Viragh Outpatient Cancer Center
Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.
Manish Agrawal is a Hematologist Oncology specialist and a Hematologist in Rockville, Maryland. Dr. Agrawal is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Urothelial Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Familial Prostate Cancer.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Childhood Iron Deficiency AnemiaDr. Marsh isDistinguished. Learn about Childhood Iron Deficiency Anemia.
- Chronic B-Cell Leukemia (CBCL)Dr. Marsh isDistinguished. Learn about Chronic B-Cell Leukemia (CBCL).
- Chronic Lymphocytic Leukemia (CLL)Dr. Marsh isDistinguished. Learn about Chronic Lymphocytic Leukemia (CLL).
- Colorectal CancerDr. Marsh isDistinguished. Learn about Colorectal Cancer.
- Endometrial CancerDr. Marsh isDistinguished. Learn about Endometrial Cancer.
- Familial Colorectal CancerDr. Marsh isDistinguished. Learn about Familial Colorectal Cancer.
- Advanced
- Adult Immune ThrombocytopeniaDr. Marsh isAdvanced. Learn about Adult Immune Thrombocytopenia.
- Adult Soft Tissue SarcomaDr. Marsh isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- AgranulocytosisDr. Marsh isAdvanced. Learn about Agranulocytosis.
- AnemiaDr. Marsh isAdvanced. Learn about Anemia.
- Angioimmunoblastic T-cell Lymphoma
- Breast CancerDr. Marsh isAdvanced. Learn about Breast Cancer.
- Experienced
- Acute Mountain SicknessDr. Marsh isExperienced. Learn about Acute Mountain Sickness.
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Marsh isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Acute Promyelocytic LeukemiaDr. Marsh isExperienced. Learn about Acute Promyelocytic Leukemia.
- ALK-Positive Non-Small Cell Lung Cancer